Search research articles
Contact Us
Filters
Showing results (21-30 of 28) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 28 results.
Cardiology
|
January 1, 1991
Diffuse aortitis complicating Behçet's disease leading to severe aortic regurgitation
Y T Tai, P C Fong, W F Ng, et al.
British Journal of Cancer
|
November 15, 2007
A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours
G Attard, J Kitzen, S P Blagden, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions
|
May 29, 1999
A prospective study of elective stenting in unprotected left main coronary disease
P Wong, V Wong, K K Tse, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 18, 2009
Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)
L R Molife, G Attard, P C Fong, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 13, 2008
Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience
D Olmos, H-T Arkenau, J E Ang, et al.
British Journal of Cancer
|
July 15, 2010
The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study
L R Molife, P C Fong, L Paccagnella, et al.
British Journal of Cancer
|
April 12, 2012
First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours
T A Yap, H Cortes-Funes, H Shaw, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 18, 2025
Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study
J N Graff, M Burotto, P C Fong, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 28) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 28 results.
Cardiology
|
January 1, 1991
Diffuse aortitis complicating Behçet's disease leading to severe aortic regurgitation
Y T Tai, P C Fong, W F Ng, et al.
British Journal of Cancer
|
November 15, 2007
A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours
G Attard, J Kitzen, S P Blagden, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions
|
May 29, 1999
A prospective study of elective stenting in unprotected left main coronary disease
P Wong, V Wong, K K Tse, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 18, 2009
Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)
L R Molife, G Attard, P C Fong, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 13, 2008
Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience
D Olmos, H-T Arkenau, J E Ang, et al.
British Journal of Cancer
|
July 15, 2010
The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study
L R Molife, P C Fong, L Paccagnella, et al.
British Journal of Cancer
|
April 12, 2012
First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours
T A Yap, H Cortes-Funes, H Shaw, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 18, 2025
Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study
J N Graff, M Burotto, P C Fong, et al.
Page
of 3